期刊文献+

盐酸吡格列酮治疗2型糖尿病的疗效及安全性 预览 被引量:14

Efficacy and Safety of Pioglitazone Hydrochloride in Treating Type 2 Diabeter
在线阅读 下载PDF
分享 导出
摘要 目的:以二甲双胍为对照,评价盐酸吡格列酮治疗2型糖尿病的疗效和安全性.方法:采用多中心、随机、双盲双模拟、平行对照的试验设计,在5个中心共收集227例2型糖尿病病人,分为吡格列酮组(113例,服用盐酸吡格列酮30mg,每日1次),和二甲双胍组(¨4例,服用盐酸二甲双胍250mg,每日2次),治疗期12周.结果:用药12周后,与基础值相比,吡格列酮组空腹血糖下降1.42±1.93mmo1.L-1(13.41%±18.65%),餐后2h血糖下降4.42±3.96mmo1.L-1(26.94%±21.32%),糖化血红蛋白下降0.80%±1.57%;二甲双胍组,空腹血糖下降1.62±2.17mmo1.L(15.45%±20.13%),餐后2h血糖下降值3.89±3.75mmo1.L-1(24.27%±21.54%),糖化血红蛋白下降0.89%±1.39%.两组血糖和糖化血红蛋白下降值与用药前比较均有显著性差异,但两组间比较无显著性差异.用药12周后,吡格列酮组,降低空腹血糖显效率40.66%,有效率75.82%,降低餐后2h血糖显效率51.38%,有效率86.24%二甲双胍组,降低空腹血糖显效率53.85%,有效率82.42%,降低餐后2h血糖显效率46.23%,有效率77.36%.两组间比较显效率和有效性均无统计学意义.两组药物不良反应发生率相似,未出现严重肝功能异常病例.结论:吡格列酮可有效地降低2型糖尿病病人的空腹血糖、餐后2h血糖和糖化血红蛋白,耐受性好,未发生严重药物不良反应. OBJECTIVE: To evaluate the efficacy and safety of pioglitazone hydrochloride in the treatment of type 2diabetes mellitus patients, a double-blind double-dummy metformin-controlled trial was carried out. METHODS:A randomized, double-blind, metformin-controlled, and multicenter clinical trial was conducted. A total of 227 patients with type 2 diabetes mellitus were enrolled in this study, in which 113 patients received pioglitazone 30mg once daily, and 114 patients received metfbrmin 250mg b.i.d, for 12 weeks. RESULTS:Comparing to the baseline, the fasting blood glucose (FBG), 2h postprandial blood glucose (P2hBG) and HbA1C levels in tow groups were significantly reduced after 12-week treatment (P<0.01). In pioglitazone group, the mean reductions of FBG, P2hBG and HbA1C levels were 1.42±1.93mmol.L-1 (13.41 ±18.65%), 4.42±3.96mmol.L-1(26.94±21.32%), 0.80±1.57% respectively, the efficacy rate of reduction of FBG and P2hBG were 75.82% and 86.24%. In metformin group, the mean reductions of FBG, P2hBG and HbA1C levels were 1.62±2.17mmol. L-1( 15.45±20.13%), 3.89±3.75mmol.L-1(24.27±21.54%), 0.89±1.39% respectively, the efficacy rate of reduction of FBG and 2hPBG were 82.42%,77.36%.,The differencesin reductions of FBG, P2hBG and HbA1C level between the groups were not statistically significant. The incidence of adverse effects in tow groups was similar. Hepatic function did not significantly change after treatment. CONCLUSION: This result provides an efficacy in glycemic control and a safety profile of pioglitazone in the treatment of type 2 diabetes mellitus.
作者 王长江 叶山东 王德全 罗佐杰 阎胜利 刘树琴 章秋 杨明功 WANG CHang-Jiang YE SHan-Dong WANG De-Quan LUO Zuo-Jie YANSHeng-Li LIU SHu-Qin ZHANG Qiu YANG Ming-Gong(Department of Endocrinology, The First Affiliated Hospital of Anhui Medical University, Hefei 230022) (Department of Endocrinology, Anhui Provincal Hospital, Hefei 230001)(Department of Endocrinology, Qilu Hospital, Shandong University, Jinan, 250001) (Department of Endocrinology, The First Affiliated Hospital of Guangxi Medical University, Manning 530001) (Department of Endocrinology, The Affiliated Hospital of Qingdao University, Qingdao 266001)
出处 《中国临床药理学杂志》 CAS 北大核心 2002年第3期 167-170,共4页 The Chinese Journal of Clinical Pharmacology
关键词 盐酸吡格列酮 治疗 2型糖尿病 疗效 安全性 diabetes mellitus,non-insulin dependent pioglitazone hydrochloride metformin
  • 相关文献

参考文献11

  • 1[1]Bretzel RG, Voigt K, Schatz H. The United Kingdom Prospective Diabetes Study(UKPDS) implications for the pharmacotherapy of type 2 diabetes mellitus. Exp Clin endocrinol Diabetes, 1998; 106:369~372. 被引量:1
  • 2[2]Haffner SM. Epdemiology of insulin resistance and its relation to coronary artery disease. American J Cardiology, 1999; 84:11 ~ 14. 被引量:1
  • 3[3]Lehmann JM, Moore LB, Smith-Oliver TA, et al. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferactor-activated receptor γ. J Biol Chem, 1995; 270:129~153. 被引量:1
  • 4[4]Hallakou S, Doare L, Foufelle F, et al. Pioglitazone induces in vivo adipocyte differentiation in the obese Zucker fa/fa rat. Diabetes,1997; 46:1393~ 1399. 被引量:1
  • 5[5]Kemnitz JW, Elson DF, Roecker EB, et al. Pioglitazone increases insulin sensitivity, reduces blood glucose, insulin, and lipid levels,and lowers blood pressure, in obese, insulin-resistant rhesus monkeys. Diabetes, 1994; 43:204~211. 被引量:1
  • 6[6]Chilcott J, Tappenden P, Jones ML, et al. A systematic review of the clinical effectiveness of pioglitazone in the treatment of type 2 diabetes mellitus. Clin Ther, 2001; 23:1792~1823. 被引量:1
  • 7[7]Rosenblatt S, Miskin B, Glazer NB, et al. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus. Coron Artery Dis, 2001; 12:413~423. 被引量:1
  • 8[8]Hanefeld M, Belcher G. Safety profile of pioglitazone. Iht J Clin Pract, 2001, 121:27~31. 被引量:1
  • 9[9]Scheen AJ. Hepatotoxicity with thiazolidinediones: is it a class effect? Drug Saf, 2001; 24 873~888. 被引量:1
  • 10[10]Einhorn D, Rendell M, Rosenzweig J, et al. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study.Clin Ther, 2000; 22:1395~1409. 被引量:1

同被引文献61

引证文献14

二级引证文献74

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部 意见反馈